Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study

2013 Noedl, 2008, Evidence of artemisinin-resistant malaria in western Cambodia, N Engl J Med, 359, 2619, 10.1056/NEJMc0805011 Dondorp, 2009, Artemisinin resistance in Plasmodium falciparum malaria, N Engl J Med, 361, 455, 10.1056/NEJMoa0808859 Ariey, 2014, A molecular marker of artemisinin-resistant Plasmodium falciparum malaria, Nature, 505, 50, 10.1038/nature12876 Ashley, 2014, Spread of artemisinin resistance in Plasmodium falciparum malaria, N Engl J Med, 371, 411, 10.1056/NEJMoa1314981 Takala-Harrison, 2015, Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in southeast Asia, J Infect Dis, 211, 670, 10.1093/infdis/jiu491 Takala-Harrison, 2013, Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in southeast Asia, Proc Natl Acad Sci USA, 110, 240, 10.1073/pnas.1211205110 Saunders, 2014, Dihydroartemisinin-piperaquine failure in Cambodia, N Engl J Med, 371, 484, 10.1056/NEJMc1403007 Cappellini, 2008, Glucose-6-phosphate dehydrogenase deficiency, Lancet, 371, 64, 10.1016/S0140-6736(08)60073-2 Bethell, 2011, Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial, PLoS One, 6, e19283, 10.1371/journal.pone.0019283 Rougemont, 2004, Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays, J Clin Microbiol, 42, 5636, 10.1128/JCM.42.12.5636-5643.2004 Manning, 2014, Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern of prolonged QTc interval, Antimicrob Agents Chemother, 58, 6056, 10.1128/AAC.02667-14 Gosi, 2013, Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in western Cambodia, Malar J, 12, 403, 10.1186/1475-2875-12-403 Rutvisuttinunt, 2012, Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates, Malar J, 11, 325, 10.1186/1475-2875-11-325 Lon, 2014, Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial, PLoS One, 9, e93138, 10.1371/journal.pone.0093138 Taylor, 2015, Absence of putative Plasmodium falciparum artemisinin resistance mutations in sub-Saharan Africa: a molecular epidemiologic study, J Infect Dis, 211, 680, 10.1093/infdis/jiu467 Plasmo Janssens, 2007, A randomized open study to assess the efficacy and tolerability of dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia, Trop Med Int Health, 12, 251, 10.1111/j.1365-3156.2006.01786.x Leang, 2013, Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010, Antimicrob Agents Chemother, 57, 818, 10.1128/AAC.00686-12 Lon, 2014, Blackwater fever in an uncomplicated Plasmodium falciparum patient treated with dihydroartemisinin-piperaquine, Malar J, 13, 96, 10.1186/1475-2875-13-96 Wongsrichanalai, 2008, Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia–Thailand border, Emerg Infect Dis, 14, 716, 10.3201/eid1405.071601 Naing, 2013, Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies, Trans R Soc Trop Med Hyg, 107, e6358, 10.1093/trstmh/trs019 2012 Zani, 2014, Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD010927 2013, The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin–piperaquine: a pooled analysis of individual patient data, PLoS Med, 10, e1001564, 10.1371/journal.pmed.1001564 Bustos, 2013, Monitoring antimalarial efficacy in the Greater Mekong subregion: an overview of in vivo results from 2008 to 2010, Southeast Asian J Trop Med Public Health, 44, 201 Thriemer, 2014, Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam, Antimicrob Agents Chemother, 58, 7049, 10.1128/AAC.02746-14 Gargano, 2011, Antimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertainties, Trop Med Int Health, 16, 1466, 10.1111/j.1365-3156.2011.02855.x Lim, 2013, Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011–2012: association with molecular markers, Antimicrob Agents Chemother, 57, 5277, 10.1128/AAC.00687-13 Teuscher, 2010, Artemisinin–induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure, J Infect Dis, 202, 1362, 10.1086/656476 Rueangweerayut, 2012, Pyronaridine-artesunate versus mefloquine plus artesunate for malaria, N Engl J Med, 366, 1298, 10.1056/NEJMoa1007125 Cottrell, 2014, Emergence of resistance to atovaquone-proguanil in malaria parasites: insights from computational modeling and clinical case reports, Antimicrob Agents Chemother, 58, 4504, 10.1128/AAC.02550-13